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Implementation ofDNA Technology
EDWARD R.B. McCABE, M.D., Ph.D.
The implementation of DNA technology for the support of newborn screening or
any other large, population-based programs will require two key components:
improved automation to reduce the personnel expenses for critical but repetitive and
tedious technical tasks and individuals who can relate to both the laboratory and the
clinical setting.
There are a number oftechnical aspects ofmolecular geneticswhich are amenable
to automation. Equipment exists at present for routine extraction of DNA from
liquid blood specimens. This equipment would need to be scaled down to meet the
requirements for microextraction of the dried blood specimens used in newborn
screening. Our group has shown that microextracted DNA from these dried blood
specimens can be used for automated direct sequencing ofthe A, S, and C alleles of
P-globin after polymerase chain reaction (PCR) amplification[1]. This approach
would be useful for detection of several allelic point mutations with a defined
genomic region. Undoubtedly it will become more feasible economically as the cost
of automated sequencing decreases in the course of the Human Genome Initiative,
and if dedicated diagnostic instrumentation is developed. Chehab and Kan have
demonstrated an elegant diagnostic approach for the A and S alleles, utilizing
competitive oligonucleotide priming (COP) and allele-specific primers labeled with
two different fluorescent dyes[2]. The products could be analyzed by an automated
sequencer of the single-lane, laser-based type or by similar automated gel-scanning
equipment which is currently under development for gel analysis of PCR products.
This latter equipment could also be utilized for detection ofalleles using avariety of
PCR-based methods targeting point mutations, insertions, and deletions, e.g., direct
digestion[3], heteroduplexformation[4], and multiplexPCR[5]. Robotic applications
for laboratory automation are also being designed[7].
The second important component which will foster broad implementation of this
technologywill be people whowill function at the clinic-laboratory interface andwill
be able to serve as facilitators and interpreters. With knowledge ofboth the clinical
and laboratory areas, these individuals will assure that appropriate specimens are
received bythe laboratory and theywill be able to interpret the results from the DNA
laboratoryfor the primary health care providers and the families. Ifthis technology is
to be accepted, information must be given to the providers and the families in a
manner that is meaningful and not intimidating. At the Institute for Molecular
Genetics at Baylor College of Medicine, we have found that genetics associates and
nurses are extremely capable in fulfilling this role. In order to meet the needs ofthis
expanding diagnostic technology, training programs must develop the requisite skills
in their trainees.
In summary, DNA technology is beginning to be utilized by newborn screening
programs for diagnostic confirmation. Broader implementation of this strategy will
require improved automation to increase its cost effectiveness and trained individu-
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alswho can assure clear and effective information transferbackto the primary health
care providers and the families.
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